Symbols / PFE Stock $26.70 +1.68% Pfizer Inc.

Healthcare • Drug Manufacturers - General • United States • NYQ
PFE (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - General
CEO Dr. Albert Bourla D.V.M., Ph.D.
Exch · Country NYQ · United States
Market Cap 151.88B
Enterprise Value 203.67B
Income 7.75B
Sales 62.58B
FCF (ttm) 13.43B
Book/sh 15.21
Cash/sh 2.39
Employees 75,000
Insider 10d —
IPO Jun 01, 1972
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 126.47%
P/E 19.63
Forward P/E 9.49
PEG 13.77
P/S 2.43
P/B 1.76
P/C —
EV/EBITDA 7.92
EV/Sales 3.25
Quick Ratio 0.80
Current Ratio 1.16
Debt/Eq 77.96
LT Debt/Eq —
EPS (ttm) 1.36
EPS next Y 2.81
EPS Growth —
Revenue Growth -1.20%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-05
Earnings (prior) 2026-02-03
ROA 5.68%
ROE 8.89%
ROIC —
Gross Margin 75.81%
Oper. Margin 23.95%
Profit Margin 12.42%
Shs Outstand 5.69B
Shs Float 5.68B
Insider Own 0.10%
Instit Own 67.96%
Short Float 2.35%
Short Ratio 3.45
Short Interest 133.41M
52W High 28.75
vs 52W High -7.13%
52W Low 21.97
vs 52W Low 21.53%
Beta 0.39
Impl. Vol. 25.39%
Rel Volume 0.95
Avg Volume 40.96M
Volume 39.03M
Target (mean) $29.00
Tgt Median $28.00
Tgt Low $24.00
Tgt High $36.00
# Analysts 27
Recom Buy
Prev Close $26.26
Price $26.70
Change 1.68%
About

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$29.00
Mean price target
2. Current target
$26.70
Latest analyst target
3. DCF / Fair value
$42.50
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$26.70
Low
$24.00
High
$36.00
Mean
$29.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-29 main Citigroup Neutral → Neutral $27
2026-04-20 reit RBC Capital Underperform → Underperform $25
2026-04-16 init CICC — → Outperform $33
2026-04-13 main UBS Neutral → Neutral $27
2026-04-10 main Morgan Stanley Equal-Weight → Equal-Weight $28
2026-04-09 main B of A Securities Neutral → Neutral $26
2026-03-24 main Guggenheim Buy → Buy $36
2026-03-17 main HSBC Buy → Buy $32
2026-03-02 up Argus Research Hold → Buy $35
2026-02-25 init RBC Capital — → Underperform $25
2026-02-20 init Barclays — → Underweight $25
2026-02-09 main Freedom Broker Buy → Buy $33
2026-02-04 reit Cantor Fitzgerald Neutral → Neutral $27
2026-01-27 main Cantor Fitzgerald Neutral → Neutral $27
2025-12-17 main Morgan Stanley Equal-Weight → Equal-Weight $27
2025-12-15 main B of A Securities Neutral → Neutral $28
2025-12-12 main Morgan Stanley Equal-Weight → Equal-Weight $28
2025-11-24 main Guggenheim Buy → Buy $35
2025-10-10 main Morgan Stanley Equal-Weight → Equal-Weight $32
2025-10-03 main B of A Securities Neutral → Neutral $30
News
RSS: Latest PFE news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-03 DAMICO JENNIFER B. Officer — 21,719 $0.00 $0
2026-02-25 BOURLA ALBERT Chief Executive Officer — 491,626 $33.82 $16,626,791
2026-02-25 DAMICO JENNIFER B. Officer — 17,558 $33.82 $593,812
2026-02-25 SAHNI PAYAL Officer — 56,888 $33.82 $1,923,952
2026-02-25 MCDERMOTT MICHAEL Officer — 37,925 $33.82 $1,282,624
2026-02-25 BOSHOFF CHRISTOFFEL Officer — 13,383 $0.00 $0
2026-02-25 FONSECA LIDIA PH.D. Officer — 56,888 $33.82 $1,923,952
2026-02-25 LANKLER DOUGLAS M Officer — 122,907 $33.82 $4,156,715
2025-03-04 DAMICO JENNIFER B. Officer — 5,583 $0.00 $0
2025-03-04 DAMICO JENNIFER B. Officer — 2,500 $25.93 $64,825
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
62,579.00
-1.65%
63,627.00
+6.84%
59,554.00
-41.14%
101,175.00
Operating Revenue
62,579.00
-1.65%
63,627.00
+6.84%
59,554.00
-41.14%
101,175.00
Cost Of Revenue
16,067.00
-9.99%
17,851.00
-28.46%
24,954.00
-27.34%
34,344.00
Reconciled Cost Of Revenue
14,349.00
-11.01%
16,124.00
-31.09%
23,397.00
-28.86%
32,889.00
Gross Profit
46,512.00
+1.61%
45,776.00
+32.30%
34,600.00
-48.23%
66,831.00
Operating Expense
29,105.00
-5.62%
30,838.00
+2.17%
30,183.00
+5.12%
28,714.00
Research And Development
10,437.00
-3.56%
10,822.00
+1.34%
10,679.00
-6.55%
11,428.00
Selling General And Administration
13,794.00
-6.35%
14,730.00
-0.28%
14,771.00
+8.00%
13,677.00
Total Expenses
45,172.00
-7.22%
48,689.00
-11.69%
55,137.00
-12.56%
63,058.00
Operating Income
17,407.00
+16.53%
14,938.00
+238.19%
4,417.00
-88.41%
38,117.00
EBITDA
16,783.00
-7.41%
18,127.00
+89.67%
9,557.00
-76.71%
41,031.00
Normalized EBITDA
25,745.00
+13.36%
22,711.00
+63.34%
13,904.00
-69.13%
45,045.00
Reconciled Depreciation
6,592.00
-6.00%
7,013.00
+11.49%
6,290.00
+24.21%
5,064.00
EBIT
10,191.00
-8.30%
11,114.00
+240.19%
3,267.00
-90.92%
35,967.00
Total Unusual Items
-8,962.00
-95.51%
-4,584.00
-5.45%
-4,347.00
-8.30%
-4,014.00
Total Unusual Items Excluding Goodwill
-8,962.00
-95.51%
-4,584.00
-5.45%
-4,347.00
-8.30%
-4,014.00
Special Income Charges
-9,160.00
-56.21%
-5,864.00
+8.56%
-6,413.00
-109.92%
-3,055.00
Other Special Charges
2,670.00
+295.56%
675.00
+1.05%
668.00
-43.53%
1,183.00
Impairment Of Capital Assets
4,940.00
+49.92%
3,295.00
+8.96%
3,024.00
+618.29%
421.00
Restructuring And Mergern Acquisition
1,550.00
-35.92%
2,419.00
-17.80%
2,943.00
+102.83%
1,451.00
Write Off
—
432.00
+90.31%
227.00
+336.54%
52.00
Net Income
7,771.00
-3.24%
8,031.00
+279.00%
2,119.00
-93.25%
31,372.00
Pretax Income
7,520.00
-6.27%
8,023.00
+658.32%
1,058.00
-96.95%
34,729.00
Net Non Operating Interest Income Expense
-2,068.00
+18.77%
-2,546.00
-335.21%
-585.00
+40.73%
-987.00
Interest Expense Non Operating
2,671.00
-13.59%
3,091.00
+39.93%
2,209.00
+78.43%
1,238.00
Net Interest Income
-2,068.00
+18.77%
-2,546.00
-335.21%
-585.00
+40.73%
-987.00
Interest Expense
2,671.00
-13.59%
3,091.00
+39.93%
2,209.00
+78.43%
1,238.00
Interest Income Non Operating
603.00
+10.64%
545.00
-66.44%
1,624.00
+547.01%
251.00
Interest Income
603.00
+10.64%
545.00
-66.44%
1,624.00
+547.01%
251.00
Other Income Expense
-7,819.00
-78.97%
-4,369.00
-57.50%
-2,774.00
-15.58%
-2,400.00
Other Non Operating Income Expenses
1,143.00
+911.50%
113.00
-89.42%
1,068.00
-9.34%
1,178.00
Gain On Sale Of Security
198.00
-84.53%
1,280.00
-38.04%
2,066.00
+315.43%
-959.00
Gain On Sale Of Business
—
525.00
+136.49%
222.00
—
Tax Provision
-266.00
-850.00%
-28.00
+97.49%
-1,115.00
-133.50%
3,328.00
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+118.75%
0.00
Tax Effect Of Unusual Items
-1,882.02
-95.51%
-962.64
-5.45%
-912.87
-136.90%
-385.34
Net Income Including Noncontrolling Interests
7,812.00
-3.10%
8,062.00
+273.59%
2,158.00
-93.13%
31,407.00
Net Income From Continuing Operation Net Minority Interest
7,746.00
-3.42%
8,020.00
+275.82%
2,134.00
-93.20%
31,366.00
Net Income From Continuing And Discontinued Operation
7,771.00
-3.24%
8,031.00
+279.00%
2,119.00
-93.25%
31,372.00
Net Income Continuous Operations
7,787.00
-3.28%
8,051.00
+270.67%
2,172.00
-93.08%
31,401.00
Net Income Discontinuous Operations
25.00
+127.27%
11.00
+173.33%
-15.00
-350.00%
6.00
Minority Interests
-41.00
-32.26%
-31.00
+20.51%
-39.00
-11.43%
-35.00
Normalized Income
14,825.98
+27.36%
11,641.36
+109.07%
5,568.13
-84.09%
34,994.66
Net Income Common Stockholders
7,771.00
-3.24%
8,031.00
+279.00%
2,119.00
-93.25%
31,372.00
Diluted EPS
1.36
-3.55%
1.41
+281.08%
0.37
-93.24%
5.47
Basic EPS
1.37
-3.52%
1.42
+273.68%
0.38
-93.20%
5.59
Basic Average Shares
5,683.00
+0.34%
5,664.00
+0.37%
5,643.00
+0.62%
5,608.00
Diluted Average Shares
5,713.00
+0.23%
5,700.00
-0.16%
5,709.00
-0.42%
5,733.00
Diluted NI Availto Com Stockholders
7,771.00
-3.24%
8,031.00
+279.00%
2,119.00
-93.25%
31,372.00
Amortization
4,874.00
-7.79%
5,286.00
+11.68%
4,733.00
+31.14%
3,609.00
Amortization Of Intangibles Income Statement
4,874.00
-7.79%
5,286.00
+11.68%
4,733.00
+31.14%
3,609.00
Depreciation Amortization Depletion Income Statement
4,874.00
-7.79%
5,286.00
+11.68%
4,733.00
+31.14%
3,609.00
Depreciation And Amortization In Income Statement
4,874.00
-7.79%
5,286.00
+11.68%
4,733.00
+31.14%
3,609.00
Earnings From Equity Interest
0.00
-100.00%
102.00
-79.80%
505.00
+15.83%
436.00
Gain On Sale Of PPE
—
—
—
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
208,160.00
-2.45%
213,396.00
-5.79%
226,501.00
+14.86%
197,205.00
Current Assets
42,898.00
-14.81%
50,358.00
+16.21%
43,333.00
-15.46%
51,259.00
Cash Cash Equivalents And Short Term Investments
13,596.00
-33.60%
20,477.00
+61.36%
12,690.00
-44.18%
22,732.00
Cash And Cash Equivalents
1,142.00
+9.49%
1,043.00
-63.44%
2,853.00
+585.82%
416.00
Other Short Term Investments
12,454.00
-35.92%
19,434.00
+97.56%
9,837.00
-55.92%
22,316.00
Receivables
15,841.00
+7.20%
14,777.00
-4.93%
15,544.00
+6.99%
14,529.00
Accounts Receivable
11,874.00
+3.59%
11,463.00
-0.89%
11,566.00
+5.61%
10,952.00
Gross Accounts Receivable
12,301.00
+3.36%
11,901.00
-1.12%
12,036.00
+5.57%
11,401.00
Allowance For Doubtful Accounts Receivable
-427.00
+2.51%
-438.00
+6.81%
-470.00
-4.68%
-449.00
Taxes Receivable
3,967.00
+19.70%
3,314.00
-16.69%
3,978.00
+11.21%
3,577.00
Inventory
10,654.00
-1.82%
10,851.00
+6.50%
10,189.00
+13.45%
8,981.00
Raw Materials
907.00
-7.07%
976.00
-3.08%
1,007.00
+17.23%
859.00
Work In Process
5,634.00
-7.65%
6,101.00
+7.26%
5,688.00
+3.06%
5,519.00
Finished Goods
4,113.00
+8.95%
3,775.00
+8.01%
3,495.00
+34.27%
2,603.00
Other Current Assets
2,807.00
-34.00%
4,253.00
-13.38%
4,910.00
-2.13%
5,017.00
Total Non Current Assets
165,263.00
+1.36%
163,038.00
-10.99%
183,168.00
+25.51%
145,944.00
Net PPE
19,317.00
+5.02%
18,393.00
-2.89%
18,940.00
+16.38%
16,274.00
Gross PPE
36,703.00
+5.24%
34,876.00
-0.31%
34,985.00
+11.25%
31,448.00
Accumulated Depreciation
-17,386.00
-5.48%
-16,483.00
-2.73%
-16,045.00
-5.74%
-15,174.00
Properties
0.00
0.00
0.00
0.00
Land And Improvements
299.00
+2.75%
291.00
-17.56%
353.00
-4.08%
368.00
Buildings And Improvements
9,744.00
+7.84%
9,036.00
-0.11%
9,046.00
+2.42%
8,832.00
Machinery Furniture Equipment
21,854.00
+6.03%
20,611.00
+4.83%
19,662.00
+13.18%
17,372.00
Construction In Progress
4,805.00
-2.67%
4,937.00
-16.68%
5,925.00
+21.54%
4,875.00
Other Properties
—
1.00
+200.00%
-1.00
-200.00%
1.00
Goodwill And Other Intangible Assets
124,994.00
+0.85%
123,939.00
-6.59%
132,683.00
+40.04%
94,745.00
Goodwill
71,264.00
+3.99%
68,527.00
+1.10%
67,783.00
+31.94%
51,375.00
Other Intangible Assets
53,730.00
-3.04%
55,412.00
-14.62%
64,900.00
+49.64%
43,370.00
Investments And Advances
1,622.00
-27.17%
2,227.00
-85.51%
15,368.00
+1.98%
15,069.00
Long Term Equity Investment
235.00
+8.29%
217.00
-98.14%
11,637.00
+5.47%
11,033.00
Other Investments
—
—
—
—
Non Current Deferred Assets
9,699.00
+11.97%
8,662.00
+133.73%
3,706.00
-44.63%
6,693.00
Non Current Deferred Taxes Assets
9,699.00
+11.97%
8,662.00
+133.73%
3,706.00
-44.63%
6,693.00
Other Non Current Assets
9,631.00
-1.89%
9,817.00
-21.28%
12,471.00
-5.26%
13,163.00
Total Liabilities Net Minority Interest
121,385.00
-2.81%
124,899.00
-8.97%
137,213.00
+35.47%
101,289.00
Current Liabilities
36,984.00
-13.98%
42,995.00
-10.04%
47,794.00
+13.42%
42,138.00
Payables And Accrued Expenses
10,788.00
-1.75%
10,980.00
-3.95%
11,431.00
+6.84%
10,699.00
Payables
10,788.00
-1.75%
10,980.00
-3.95%
11,431.00
+6.84%
10,699.00
Accounts Payable
5,240.00
-6.98%
5,633.00
-16.05%
6,710.00
-1.45%
6,809.00
Dividends Payable
2,445.00
+0.33%
2,437.00
+2.74%
2,372.00
+3.00%
2,303.00
Employee Benefits
2,041.00
-3.50%
2,115.00
-2.40%
2,167.00
-3.69%
2,250.00
Pensionand Other Post Retirement Benefit Plans Current
3,610.00
-5.94%
3,838.00
+38.26%
2,776.00
-18.52%
3,407.00
Total Tax Payable
3,103.00
+6.63%
2,910.00
+23.88%
2,349.00
+48.02%
1,587.00
Income Tax Payable
3,103.00
+6.63%
2,910.00
+23.88%
2,349.00
+48.02%
1,587.00
Current Debt And Capital Lease Obligation
3,154.00
-54.59%
6,946.00
-32.86%
10,346.00
+252.62%
2,934.00
Current Debt
3,154.00
-54.59%
6,946.00
-32.86%
10,346.00
+252.62%
2,934.00
Other Current Borrowings
3,154.00
-29.80%
4,493.00
+88.70%
2,381.00
-18.85%
2,934.00
Current Deferred Liabilities
784.00
-48.11%
1,511.00
-44.04%
2,700.00
+7.14%
2,520.00
Current Deferred Revenue
784.00
-48.11%
1,511.00
-44.04%
2,700.00
+7.14%
2,520.00
Other Current Liabilities
18,648.00
-5.44%
19,720.00
-4.00%
20,541.00
-9.02%
22,578.00
Total Non Current Liabilities Net Minority Interest
84,401.00
+3.05%
81,904.00
-8.40%
89,419.00
+51.17%
59,151.00
Long Term Debt And Capital Lease Obligation
60,807.00
+7.24%
56,703.00
-6.27%
60,499.00
+89.50%
31,925.00
Long Term Debt
60,807.00
+7.24%
56,703.00
-6.27%
60,499.00
+89.50%
31,925.00
Non Current Pension And Other Postretirement Benefit Plans
2,041.00
-3.50%
2,115.00
-2.40%
2,167.00
-3.69%
2,250.00
Tradeand Other Payables Non Current
3,591.00
-41.25%
6,112.00
-28.38%
8,534.00
-13.02%
9,812.00
Non Current Deferred Liabilities
2,401.00
+13.15%
2,122.00
+231.56%
640.00
-37.44%
1,023.00
Non Current Deferred Taxes Liabilities
2,401.00
+13.15%
2,122.00
+231.56%
640.00
-37.44%
1,023.00
Other Non Current Liabilities
14,727.00
+4.07%
14,151.00
-14.44%
16,540.00
+25.47%
13,182.00
Stockholders Equity
86,476.00
-1.96%
88,203.00
-0.91%
89,014.00
-6.95%
95,661.00
Common Stock Equity
86,476.00
-1.96%
88,203.00
-0.91%
89,014.00
-6.95%
95,661.00
Capital Stock
481.00
+0.21%
480.00
+0.42%
478.00
+0.42%
476.00
Common Stock
481.00
+0.21%
480.00
+0.42%
478.00
+0.42%
476.00
Preferred Stock
—
—
0.00
0.00
Share Issued
9,621.00
+0.29%
9,592.99
+0.32%
9,562.00
+0.45%
9,519.00
Ordinary Shares Number
5,686.00
+0.34%
5,666.99
+0.37%
5,646.00
+0.53%
5,616.00
Treasury Shares Number
3,935.00
+0.23%
3,926.00
+0.26%
3,916.00
+0.33%
3,903.00
Additional Paid In Capital
94,469.00
+0.93%
93,603.00
+1.05%
92,631.00
+0.90%
91,802.00
Retained Earnings
114,610.00
-1.81%
116,725.00
-1.38%
118,353.00
-5.81%
125,656.00
Gains Losses Not Affecting Retained Earnings
-8,070.00
-2.91%
-7,842.00
+1.49%
-7,961.00
+4.13%
-8,304.00
Treasury Stock
115,015.00
+0.22%
114,763.00
+0.24%
114,487.00
+0.45%
113,969.00
Minority Interest
299.00
+1.70%
294.00
+7.30%
274.00
+7.03%
256.00
Other Equity Adjustments
-321.00
-663.16%
57.00
+126.27%
-217.00
+47.33%
-412.00
Total Equity Gross Minority Interest
86,775.00
-1.95%
88,497.00
-0.89%
89,288.00
-6.91%
95,916.00
Total Capitalization
147,283.00
+1.64%
144,906.00
-3.08%
149,513.00
+17.19%
127,586.00
Working Capital
5,914.00
-19.68%
7,363.00
+265.05%
-4,461.00
-148.91%
9,121.00
Invested Capital
150,437.00
-0.93%
151,852.00
-5.01%
159,859.00
+22.48%
130,520.00
Total Debt
63,961.00
+0.49%
63,649.00
-10.16%
70,845.00
+103.23%
34,859.00
Net Debt
62,819.00
+0.34%
62,606.00
-7.92%
67,992.00
+97.40%
34,443.00
Net Tangible Assets
-38,518.00
-7.78%
-35,736.00
+18.17%
-43,669.00
-4867.36%
916.00
Tangible Book Value
-38,518.00
-7.78%
-35,736.00
+18.17%
-43,669.00
-4867.36%
916.00
Available For Sale Securities
1,339.00
-31.86%
1,965.00
-46.66%
3,684.00
-7.62%
3,988.00
Commercial Paper
0.00
-100.00%
2,453.00
-69.20%
7,965.00
0.00
Derivative Product Liabilities
834.00
+18.97%
701.00
-32.53%
1,039.00
+8.34%
959.00
Foreign Currency Translation Adjustments
-7,796.00
+2.35%
-7,984.00
-1.54%
-7,863.00
+5.94%
-8,360.00
Held To Maturity Securities
48.00
+6.67%
45.00
-4.26%
47.00
-2.08%
48.00
Investmentin Financial Assets
1,387.00
-31.00%
2,010.00
-46.13%
3,731.00
-7.56%
4,036.00
Minimum Pension Liabilities
75.00
-60.73%
191.00
+49.22%
128.00
-48.39%
248.00
Other Equity Interest
1.00
—
—
—
Other Inventories
—
-1.00
+0.00%
-1.00
—
Unrealized Gain Loss
-28.00
+73.58%
-106.00
-1077.78%
-9.00
-104.09%
220.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
11,704.00
-8.16%
12,744.00
+46.48%
8,700.00
-70.27%
29,267.00
Cash Flow From Continuing Operating Activities
11,705.00
-8.15%
12,743.00
+46.44%
8,702.00
-70.27%
29,267.00
Cash From Discontinued Operating Activities
—
—
0.00
0.00
Net Income From Continuing Operations
7,787.00
-3.28%
8,051.00
+270.50%
2,173.00
-93.08%
31,401.00
Depreciation Amortization Depletion
6,592.00
-6.00%
7,013.00
+11.49%
6,290.00
+24.21%
5,064.00
Depreciation And Amortization
6,592.00
-6.00%
7,013.00
+11.49%
6,290.00
+24.21%
5,064.00
Other Non Cash Items
-1,257.00
+44.65%
-2,271.00
+46.95%
-4,281.00
-970.25%
-400.00
Stock Based Compensation
799.00
-8.89%
877.00
+67.05%
525.00
-39.79%
872.00
Asset Impairment Charge
5,270.00
+24.23%
4,242.00
-55.84%
9,607.00
+454.36%
1,733.00
Deferred Tax
-2,133.00
-1.47%
-2,102.00
+38.93%
-3,442.00
+8.55%
-3,764.00
Deferred Income Tax
-2,133.00
-1.47%
-2,102.00
+38.93%
-3,442.00
+8.55%
-3,764.00
Change In Working Capital
-5,354.00
-74.62%
-3,066.00
-41.16%
-2,172.00
+61.48%
-5,639.00
Change In Receivables
-263.00
-141.28%
-109.00
-131.41%
347.00
+32.95%
261.00
Changes In Account Receivables
-263.00
-141.28%
-109.00
-131.41%
347.00
+32.95%
261.00
Change In Inventory
561.00
+165.69%
-854.00
+26.95%
-1,169.00
-97.80%
-591.00
Change In Payables And Accrued Expense
-469.00
+54.15%
-1,023.00
-241.00%
-300.00
-125.19%
1,191.00
Change In Payable
-469.00
+54.15%
-1,023.00
-241.00%
-300.00
-125.19%
1,191.00
Change In Account Payable
-469.00
+54.15%
-1,023.00
-241.00%
-300.00
-125.19%
1,191.00
Change In Other Working Capital
-2,805.00
-108.55%
-1,345.00
-36.97%
-982.00
-80.18%
-545.00
Change In Other Current Assets
1,289.00
-61.86%
3,380.00
+609.80%
-663.00
+85.29%
-4,506.00
Change In Other Current Liabilities
-3,667.00
-17.72%
-3,115.00
-623.53%
595.00
+141.06%
-1,449.00
Investing Cash Flow
-1,351.00
-150.94%
2,652.00
+108.22%
-32,278.00
-104.51%
-15,783.00
Cash Flow From Continuing Investing Activities
-1,351.00
-150.90%
2,654.00
+108.22%
-32,277.00
-104.50%
-15,783.00
Cash From Discontinued Investing Activities
—
—
0.00
0.00
Net PPE Purchase And Sale
-2,629.00
+9.63%
-2,909.00
+25.54%
-3,907.00
-20.74%
-3,236.00
Purchase Of PPE
-2,629.00
+9.63%
-2,909.00
+25.54%
-3,907.00
-20.74%
-3,236.00
Capital Expenditure
-2,629.00
+9.63%
-2,909.00
+25.54%
-3,907.00
-20.74%
-3,236.00
Net Investment Purchase And Sale
1,729.00
+216.90%
-1,479.00
-109.71%
15,239.00
+128.06%
6,682.00
Purchase Of Investment
-17,325.00
-67.99%
-10,313.00
+66.92%
-31,178.00
+19.60%
-38,780.00
Sale Of Investment
19,054.00
+115.69%
8,834.00
-80.97%
46,417.00
+2.10%
45,462.00
Net Business Purchase And Sale
-616.00
-108.75%
7,040.00
+116.21%
-43,430.00
-88.85%
-22,997.00
Purchase Of Business
-6,927.00
0.00
+100.00%
-43,430.00
-88.85%
-22,997.00
Net Other Investing Changes
165.00
—
-180.00
+6.25%
-192.00
Financing Cash Flow
-10,304.00
+39.88%
-17,140.00
-165.76%
26,066.00
+275.72%
-14,834.00
Cash Flow From Continuing Financing Activities
-10,303.00
+39.89%
-17,140.00
-165.75%
26,067.00
+275.72%
-14,834.00
Net Issuance Payments Of Debt
-74.00
+98.97%
-7,159.00
-119.92%
35,945.00
+1122.33%
-3,516.00
Issuance Of Debt
9,678.00
+8.66%
8,907.00
-76.88%
38,517.00
+889.90%
3,891.00
Repayment Of Debt
-9,752.00
+39.30%
-16,066.00
-524.65%
-2,572.00
+65.28%
-7,407.00
Long Term Debt Issuance
9,678.00
0.00
-100.00%
30,831.00
0.00
Long Term Debt Payments
-6,757.00
-200.31%
-2,250.00
+12.42%
-2,569.00
+22.10%
-3,298.00
Net Long Term Debt Issuance
2,921.00
+229.82%
-2,250.00
-107.96%
28,262.00
+956.94%
-3,298.00
Short Term Debt Issuance
0.00
-100.00%
8,907.00
+15.89%
7,686.00
+97.53%
3,891.00
Short Term Debt Payments
-2,995.00
+78.32%
-13,816.00
-460433.33%
-3.00
+99.93%
-4,109.00
Net Short Term Debt Issuance
-2,995.00
+38.99%
-4,909.00
-163.89%
7,683.00
+3624.31%
-218.00
Net Common Stock Issuance
—
0.00
0.00
+100.00%
-2,000.00
Common Stock Payments
—
0.00
0.00
+100.00%
-2,000.00
Common Stock Dividend Paid
-9,771.00
-2.72%
-9,512.00
-2.87%
-9,247.00
-2.94%
-8,983.00
Cash Dividends Paid
-9,771.00
-2.72%
-9,512.00
-2.87%
-9,247.00
-2.94%
-8,983.00
Repurchase Of Capital Stock
—
0.00
0.00
+100.00%
-2,000.00
Net Other Financing Charges
-459.00
+2.13%
-469.00
+25.79%
-632.00
-88.66%
-335.00
Changes In Cash
49.00
+102.81%
-1,744.00
-170.07%
2,489.00
+284.37%
-1,350.00
Effect Of Exchange Rate Changes
41.00
+162.12%
-66.00
-65.00%
-40.00
+75.76%
-165.00
Beginning Cash Position
1,107.00
-62.05%
2,917.00
+523.29%
468.00
-76.40%
1,983.00
End Cash Position
1,197.00
+8.13%
1,107.00
-62.05%
2,917.00
+523.29%
468.00
Free Cash Flow
9,075.00
-7.73%
9,835.00
+105.20%
4,793.00
-81.59%
26,031.00
Interest Paid Supplemental Data
2,739.00
-15.12%
3,227.00
+45.69%
2,215.00
+53.61%
1,442.00
Income Tax Paid Supplemental Data
4,688.00
+30.04%
3,605.00
+14.55%
3,147.00
-60.00%
7,867.00
Dividends Received CFI
—
0.00
0.00
-100.00%
3,960.00
Earnings Losses From Equity Investments
—
—
—
—
Sale Of Business
6,311.00
-10.36%
7,040.00
0.00
0.00
Cash From Discontinued Financing Activities
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category